Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels

Journal of Diabetes Science and Technology

Volumn 9, Issue 4, 2015, Pages 808-814

  Burton, Jeffrey H ^a   Johnson, Matthew ^a,b   Johnson, Jolene ^b   Hsia, Daniel S ^a   Greenway, Frank L ^a   Heiman, Mark L ^c  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Microbiome Therapeutics   (United States)

Author keywords

GI adverse events; Glucose; Metformin; Metformin intolerance; Microbiome modulator; NM504

Indexed keywords

GLIMEPIRIDE; METFORMIN; ANTIDIABETIC AGENT; BETA GLUCAN; GLUCOSE BLOOD LEVEL; INULIN; PLANT EXTRACT; POLYPHENOL;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CROSSOVER PROCEDURE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE FLORA; MALE; MIDDLE AGED; QUESTIONNAIRE; SCREENING; AGED; ANALYSIS; BLOOD; CHEMISTRY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; ELEMENTAL DIET; GLUCOSE TOLERANCE TEST; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BETA-GLUCANS; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOOD, FORMULATED; GASTROINTESTINAL MICROBIOME; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INULIN; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; PLANT EXTRACTS; POLYPHENOLS; TREATMENT OUTCOME;

EID: 85016478565     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815577425     Document Type: Article

References (32)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2015; 38: 140-149.
2. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
3. Zhou G, Meyers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin. J Clin Invest. 2001;108:1167-1174.
4. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542-546.
5. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122:112-120.
6. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab. 2011;37:90-96.
7. Glucophage (metformin hydrochloride) and Glucophage XR (extended-release) prescribing information. Bristol, NJ: Bristol-Myers Squibb; 2009.
8. Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int. 1996;49:1-8.
9. Gennari FJ, Weise WJ. Acid-base disturbances in gastrointestinal disease. Clin J Am Soc Nephrol. 2008;3:18618.
10. Qin J, Li Y, Cai Z, Li S, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55-60.
11. Greenway F, Wang S, Heiman M. A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. Beneficial Microbes. 2014;5:29-32.
12. Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome global improvement scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003;48:1317-1323.
13. Whelan K, Judd PA, Taylor MA. Assessment of fecal output in patients receiving enteral tube feeding: validation of a novel chart. Eur J Clin Nutr. 2004;58:1030-1037.
14. Fillinger S, Boschi-Muller S, Azza S, Dervn E, Branlant G, Aymerich S. Two glyceraldehyde-3-phosphate dehydrogenases with opposite physiological roles in a nonphotosynthetic bacterium. J Biol Chem. 2000;275:14031-14037.
15. Stolberg L, Rolfe R, Gitlin N, et al. d-Lactic acidosis due to abnormal gut flora: diagnosis and treatment of two cases. N Engl J Med. 1982;306:1344-1348.
16. Hove H, Mortensen PB. Colonic lactate metabolism and d-lactic acidosis. Dig Dis Sci. 1995;40:320-330.
17. Kelly OB, Mroz MS, Ward JB, et al. Ursodeoxycholic acid attenuates colonic epithelial secretory function. J Physiol. 2013;591(pt 9):2307-2318.
18. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes metllitus. Diabet Med. 1998;15:651-656.
19. Kim HJ, White PJ. Interactional effects of β-glucan, starch, and protein in heated oat slurries on viscosity and in vitro bile acid binding. J Agric Food Chem. 2012;60:6217-6222.
20. Bolam DN, Sonnenburg JL. Mechanistic insight into polysaccharide use within the intestinal microbiota. Gut Microbes. 2011;2:86-90.
21. Covington DK, Briscoe CA, Brown AJ, Jayawickreme CK. The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochem Soc Trans. 2006;34:770-773.
22. Karaki S, Mitsui R, Hayashi H, et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res. 2006;324:353-360.
23. Li RL, Sherbet DP, Elsbernd DL, Goldstein JL, Brown MS, Zhao TJ. Profound hypoglycemia in starved, ghrelin-deficient mice is caused by decreased gluconeogenesis and reversed by lactate or fatty acids. J Biol Chem. 2012;287:17942-17950.
24. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
25. Kirchner H, Gutierrez JA, Solenberg PJ, et al. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med. 2009;15:741-745.
26. Matsumoto M, Hosoda H, Kitajima Y, et al. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun. 2001;287:142-146.
27. Fukumori R, Sugino T, Hasegawa Y, et al. Plasma ghrelin concentration is decreased by short chain fatty acids in wethers. Domest Anim Endocrinol. 2011;41:50-55.
28. Wang SY, Chen H, Ehlenfeldt MK. Antioxidant capacities vary substantially among cultivars of rabbiteye blueberry (Vaccinium ashei Reade). Int J Food Sci Tech. 2011;46:2482-2490.
29. Rodriquez-Mateos A, Cifuentes-Gomez T, Tabatabaee S, Lecras C, Spencer JPE. Procyanidin, anthocyanin, and chlorogenic acid contents of highbush and lowbush blueberries. J Agric Food Chem. 2012;60:5772-5778.
30. Del BC, Ciappellano S, Klimis-Zacas D, et al. Anthocyanin absorption, metabolism, and distribution from a wild blueberry-enriched diet (Vaccinium angustifolium) is affected by diet dyration in the Sprague-Dawley rat. J Agric Food Chem. 2010;58:2491-2497.
31. Hidalgo M, Oruna-Concha MJ, Kolida S, et al. Metabolism of anthocyanins by human gut microflora and the influence on gut bacterial growth. J Agric Food Chem. 2012;60:3882-3890.
32. Stull AJ, Cash KC, Johnson WD, Champagne CM, Cefalu WT. Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. J Nutr. 2010;140: 1764-1768.